Bruker BioSciences Non-Affiliated Shareholders Overwhelmingly Approve Acquisition of Bruker BioSpin Group
26 February 2008 - 2:49AM
Business Wire
After the Company�s Special Stockholders Meeting held this morning
in Boston, Bruker BioSciences Corporation (NASDAQ: BRKR) announces
that its stockholders have approved the acquisition of the
companies comprising the Bruker BioSpin Group. At today�s Special
Meeting all proposals were approved with overwhelming majorities by
the Bruker BioSciences stockholders. In particular, the three
proposals for the acquisition of the Bruker BioSpin Group companies
were each approved by a majority of greater than 99% of the BRKR
shareholders not affiliated with the controlling shareholders of
BRKR and who voted at the meeting. In addition to approving the
acquisition of the Bruker BioSpin Group, stockholders approved
amendments to the Company�s certificate of incorporation to, among
other things, change the name of the Company to �Bruker
Corporation�. Moreover, Dr. Tony W. Keller and Dirk D. Laukien,
Ph.D. were elected to serve as directors of Bruker Corporation.
Frank Laukien, President and CEO of Bruker BioSciences, stated: �We
are very pleased to receive this clear vote and mandate from our
non-affiliated shareholders to move forward with the acquisition of
the Bruker BioSpin Group, which is now expected to close in
February. The Bruker BioSpin Group is very complementary to Bruker
BioSciences and the transaction should allow us to expand our
combined market reach, leverage the Bruker brand, and enhance our
ability to grow our profitability and cash flows.� CAUTIONARY
STATEMENT OF BRUKER BIOSCIENCES Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Any forward-looking
statements contained herein are based on current expectations, but
are subject to a number of risks and uncertainties. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the integration of businesses we have
acquired or may acquire in the future, changing technologies,
product development and market acceptance of our products, the cost
and pricing of our products, manufacturing, competition, dependence
on collaborative partners and key suppliers, capital spending and
government funding policies, changes in governmental regulations,
intellectual property rights, litigation, and exposure to foreign
currency fluctuations. These and other factors are identified and
described in more detail in our filings with the SEC, including,
without limitation, our annual report on Form 10-K for the year
ended December 31, 2006, our most recent quarterly reports on Form
10-Q and our current reports on Form 8-K. We disclaim any intent or
obligation to update these forward-looking statements other than as
required by law.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024